PMID- 29950866
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230911
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 11
DP  - 2018
TI  - MYO5A inhibition by miR-145 acts as a predictive marker of occult neck lymph node 
      metastasis in human laryngeal squamous cell carcinoma.
PG  - 3619-3635
LID - 10.2147/OTT.S164597 [doi]
AB  - INTRODUCTION: Each year, ~50,000 patients worldwide die of laryngeal squamous 
      cell carcinoma (LSCC) because of its highly metastatic properties. However, its 
      pathogenic mechanisms are still unclear, and in particular, the prediction of 
      metastasis remains elusive. This study aimed to define the role of microRNA-145 
      (miR-145) in LSCC progression. We also aimed to elucidate the clinical 
      significance of the miR-145/MYO5A pathway, especially the predictive function of 
      MYO5A in neck lymph node metastasis. MATERIALS AND METHODS: MYO5A and miR-145 
      expression was analyzed in 132 patients with LSCC, and associations between their 
      expression and clinicopathological features were evaluated. We validated the 
      regulatory relationship between miR-145b and MYO5A by dual luciferase reporter 
      assay. The role of the miR-145/MYO5A pathway in proliferation, metastasis, and 
      apoptosis was examined in vitro. The predictive functions of MYO5A in neck lymph 
      node metastasis and prognosis were defined according to patient follow-up. 
      RESULTS: Our results showed downregulation of miR-145 in LSCC, which was 
      negatively correlated with MYO5A suppression of LSCC progression and metastasis. 
      MiR-145 directly regulated MYO5A expression in vitro and suppressed LSCC 
      proliferation and invasion while promoting apoptosis by inhibiting MYO5A. 
      CONCLUSION: Notably, overexpression of serum MYO5A in LSCC predicted cervical 
      nodal occult metastasis and poor prognosis, providing an effective indicator for 
      predicting neck lymph node metastasis and assessing LSCC prognosis.
FAU - Zhao, Xudong
AU  - Zhao X
AD  - Department of Otorhinolaryngology, Shengjing Hospital, China Medical University, 
      Shenyang, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Endocrinology, Shengjing Hospital, China Medical University, 
      Shenyang, China.
FAU - Ji, Wenyue
AU  - Ji W
AD  - Department of Otorhinolaryngology, Shengjing Hospital, China Medical University, 
      Shenyang, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20180621
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
RIN - Onco Targets Ther. 2023 Sep 05;16:729-730. PMID: 37694106
PMC - PMC6016585
OTO - NOTNLM
OT  - MYO5A
OT  - laryngeal cancer
OT  - laryngeal squamous cell carcinoma
OT  - miR-145
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/06/29 06:00
MHDA- 2018/06/29 06:01
PMCR- 2018/06/21
CRDT- 2018/06/29 06:00
PHST- 2018/06/29 06:00 [entrez]
PHST- 2018/06/29 06:00 [pubmed]
PHST- 2018/06/29 06:01 [medline]
PHST- 2018/06/21 00:00 [pmc-release]
AID - ott-11-3619 [pii]
AID - 10.2147/OTT.S164597 [doi]
PST - epublish
SO  - Onco Targets Ther. 2018 Jun 21;11:3619-3635. doi: 10.2147/OTT.S164597. 
      eCollection 2018.